Last July we announced our investment in Flourish Care, a maternal healthcare technology platform delivering one-on-one doula support fully covered by insurance. We wrote then that doula care was an overlooked opportunity, and that we expected the market to open as states implemented reimbursement. One year later, that is exactly what has happened, faster than even we expected.
A Market That Has Arrived
Doula care has crossed from advocacy-driven pilot programs into a reimbursed, institutionally backed category. Flourish notes that 46 states have now taken steps toward Medicaid coverage for doula care, and the National Health Law Program (NHeLP) counts 26 states plus DC already reimbursing today, up from just two states before 2020. The commercial market has followed. UnitedHealthcare expanded its doula benefit to employer-sponsored plans nationwide this spring, projecting that roughly 7.2 million members may have access by January 2027. Elevance has moved doulas into its employer plan networks, searchable like any in-network provider, alongside Medicaid coverage in ten states. When the country's largest insurers build a benefit into their networks, a market is forming. We are bullish on this category, and we invested behind that conviction.
The opportunity is large and barely tapped. Roughly 4 million people give birth in the U.S. each year, and Medicaid finances about 41% of those births, per KFF. Yet only a small share of eligible women currently receive doula care. Complications related to pregnancy and childbirth cost the U.S. an estimated $32.3 billion from pregnancy through a child's fifth birthday. Prevention at the bedside attacks some of the most expensive events in the entire maternity episode.
The Evidence Behind the Coverage
Payers aren't expanding doula coverage out of goodwill. The clinical case is now published and hard to argue with. A 2024 study in the American Journal of Public Health, drawn from national Medicaid claims data, found that women who received doula care had a 47% lower risk of cesarean (C-section) delivery, a 29% lower risk of preterm birth, and were 46% more likely to attend a postpartum checkup. In counties with high infant mortality, the effect was even larger: C-sections dropped 57% for women with doula support.
The mental health findings are just as compelling. Elevance's research found that women who began doula care in their first trimester experienced significantly lower postpartum anxiety and depression. The evidence keeps building. A new systematic review of 22 studies published in JAMA Network Open in April 2026 found doula support most consistently associated with reduced maternal anxiety, higher breastfeeding initiation, and better postpartum follow-up care. This is the evidence backbone the whole category now cites, and it explains why CMS, ACOG, and the WHO all recommend doula care. The numbers match what mothers tell Flourish. As one put it on the company’s website: “My doctor listened more when my doula was in the room.” However, the gap between what the evidence supports and what women actually receive remains enormous. That gap is the opportunity we underwrote.
How Flourish Has Grown
Flourish has grown right alongside the market. In March, the company announced an oversubscribed $5.7 million seed round led by Zeal Capital Partners, with participation from Create Health Ventures, Collide Capital, Rogue Women's Fund, Symphonic Capital, Slater Technology Fund, Catalytic Impact Foundation, and Capita3. Flourish now operates one of the largest high-quality doula networks in the country, with credentialed doulas across 18 states, and has gone in network with UnitedHealthcare as that national benefit scales. That's exactly the kind of key customer contract we predicted in our announcement a year ago.
The model is the same one we backed, now at greater scale and more technology-driven than most people realize. Flourish's platform matches expecting and new mothers with a doula chosen for cultural fit, language, and location, then supports them in person, over telehealth, and through 24/7 text across an 18-month program from pregnancy through the first year postpartum. It's free to patients and practices because insurance pays for it, and behind that experience sits real infrastructure: the platform handles credentialing, matching, billing, and care coordination, and plugs into the workflows of health plans, hospitals, and OB practices. Because doulas are in the home between clinical visits, they capture information no one else sees, and Flourish is building on that data to identify higher-risk patients and intervene earlier. We believe that combination, genuine in-person capability plus a data platform underneath it, is what separates durable operators in this category from the virtual-first platforms, and increasingly it's what payers want at the contracting table.
Why This Matters for Capita3
Flourish sits squarely in Capita3's upstream health thesis: get in front of disease and cost by investing where care actually happens, in the home and in the community, not just the clinic or hospital. Maternal health is one of the clearest examples of a system that spends enormous sums on preventable complications while underinvesting in the support that prevents them. Doula care flips that equation, and the payers have finally caught up to the evidence.
Founder and CEO Melissa Bowley has executed on everything we saw in this team a year ago. She left a career in medical devices to build Flourish after her own experience with a doula, and she's turning what was once a private-pay luxury into a covered benefit for every family. The policy tailwinds are strong and the clinical evidence keeps compounding. The company is scaling into the opening, and the next twelve months look even better than the last. Watch this space!
